Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI” or the "Company”) (Nasdaq: ANIP) today ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in ...

A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (LSE:0A88) from Outperform to Market Perform. There are 554 funds or institutions reporting ...